AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

International Rare And Severe Psoriasis Expert Network

Recruitingn/aAges 6 Months - anyAllUniversity Hospital, Basel, Switzerland
💬

In plain words

What the trial is, and whether it could suit you

This registry is a prospective observational study in order to describe primarily the natural course of PP subtypes and to gain detailed information about their phenotype.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Written informed consent of the patient or legal proxy in the registry * Diagnosis of PP confirmed by a dermatologist in the participant. The type of PP can be any one of PPP, GPP/Acute Generalized Exanthematous Pustulosis (AGEP), ACH or a mixed phenotype, according to the judgment of the investigator * GPP: Primary, sterile, macroscopically visible epidermal pustules on non-acral Skin with or without systemic Inflammation; with or without plaque psoriasis; either relapsing (\>1 episode) or persistent (\>3 months) * PPP: Primary, persistent (\>3 months), sterile, macroscopically visible epidermal pustules on palms and/or soles with or without plaque psoriasis * ACH: Primary, persistent (\>3 months), sterile, macroscopically visible epidermal pustules affecting the nail apparatus with or without plaque psoriasis * At the timepoint of inclusion, the participant must have had active pustulation with either white, yellow or brown pustules within six month before baseline. Active postulation at baseline is not mandatory for inclusion. * Sufficient language skills (in the languages which the patient information and the consent form is available) for the informed consent to participate * Patients of all ancestries and skin pigment type can be included * Direct non-affected adult (\>18 years old) relatives of the participant (up to two, namely mother, father, sibling) with the purpose to provide DNA for family trio sequencing analysis. The patient is not excluded from the study if no relatives are included. Exclusion Criteria: * Any medical or psychological condition in the treating physician's opinion which may prevent the patient in registry participation for the next 5 years * Lack of informed consent for registry participation
💊

What it tests

  • biological sampling
  • Phenotypic description
  • Photography
📍

Where

8 sites
Klinikum der Universität München
München, Germany
Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS
Rome, Italy
Universitário do Porto
Porto, Portugal
National Skin Centre
Singapore, Singapore
Dermatology, University Hospital Basel
Basel, Switzerland
University Hospital Zürich
Zurich, Switzerland
Akdeniz University School of Medicine; Department of Dermatology and Venereology
Antalya, Turkey (Türkiye)
Trakya University, Faculty of Medicine; Department of Dermatology and Venereology
Edirne, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy